Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

News

1 - 10of about 629 News

1 - 10of about 629 News

July 21, 2021

Not intended for U.S. and UK Media

Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU

July 09, 2021

Not intended for U.S. and UK Media

U.S. FDA approves finerenone for the treatment of patients with chronic kidney disease associated with type 2 diabetes

June 23, 2021

Not intended for U.S. and UK Media

Vericiguat approved in Japan to treat patients with chronic heart failure

June 21, 2021

Not intended for U.S. and UK Media

Bayer submits regulatory applications for oncology treatment combination of copanlisib and rituximab in the U.S. and EU

June 08, 2021

Bayer to advance two first-of-its-kind cell and gene therapies for Parkinson’s disease

June 03, 2021

Not intended for U.S. and UK Media

Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer

May 27, 2021

Bayer announces five-point plan to effectively address potential future Roundup™ claims

May 25, 2021

Not intended for U.S. and UK Media

Precision oncology treatment Larotrectinib submitted for marketing authorization in China

May 21, 2021

Not intended for U.S. and UK Media

Positive CHMP opinion for Bayer’s new symptomatic chronic heart failure treatment vericiguat

May 19, 2021

Not intended for U.S. and UK Media - ASCO Annual Meeting 2021:

Long-term data on Vitrakvi™ (larotrectinib) confirm sustained clinical benefit of greater than four years in patients with TRK fusion cancer regardless of tumor type and age

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases